Table 1.
Baseline demographics and clinical characteristics of patients
| Characteristics | No. of patients (n = 118) | % |
|---|---|---|
| Gender | ||
| Female | 22 | 18.64 |
| Male | 96 | 81.36 |
| Age | ||
| ≤60 | 59 | 50.00 |
| >60 | 59 | 50.00 |
| Tumor stage | ||
| T1-T2 | 26 | 22.03 |
| T3-T4 | 92 | 77.97 |
| Lymph node metastasis | ||
| N0 | 43 | 36.44 |
| N1-N3 | 75 | 63.56 |
| Adjuvant chemotherapy after surgery | ||
| No | 69 | 58.47 |
| Yes | 49 | 41.53 |
| Neoadjuvant chemotherapy | ||
| No | 105 | 88.98 |
| Yes | 13 | 11.02 |
| Concurrent chemotherapy | ||
| No | 74 | 62.71 |
| Yes | 44 | 37.29 |
| Adjuvant chemotherapy | ||
| No | 58 | 49.15 |
| Yes | 60 | 50.85 |
| Treatment response | ||
| CR | 14 | 11.86 |
| PR | 43 | 36.44 |
| SD | 49 | 41.53 |
| PD | 12 | 10.17 |
| Adverse events after treatment | ||
| I-II | 106 | 89.83 |
| III-IV | 12 | 10.17 |
| Median | Range | |
| Age | 61 | 37–79 |
| Total Dose of Radiotherapy | 60 | 45–66 |
| Total Numbers of Chemotherapy Cycle | 2 | 0–10 |
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.